Recent Updates — RGEN
Repligen Corporation announced the issuance of $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 through privately negotiated agreements with existing holders of its 1.00% Convertible Senior Notes due 2028 and new investors. Approximately $541.4 million in new notes will be issued in exchange for $456.8 million in old notes, while approximately $458.6 million will be issued for cash. The transaction is expected to close on or about November 6, 2026. Repligen intends to use roughly $120.0 million of the net proceeds from the cash subscription to repurchase common stock at $188.64 per share to facilitate the exchange. The new notes carry an initial conversion price of approximately $226.37 per share, representing a 20% premium to the October 29 closing price. Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies for biologics manufacturing.
Repligen Corporation reported third-quarter revenue of $209.3 million, an 11% increase as reported and 12.5% organic growth compared to the prior year period. The company posted a GAAP loss per share of $0.68 due primarily to a $41.2 million intangible asset impairment charge, while adjusted earnings per share were $0.53. Repligen also raised its full-year 2026 revenue guidance to $844-$852 million, reflecting strong demand and the recent acquisition of BioLife Solutions. The company operates in the bioprocessing industry, developing technologies for biologics manufacturing.
Repligen Corporation completed its previously announced acquisition of BioLife Solutions, Inc., on October 6, 2026. Under the terms of the merger agreement, holders of BioLife common stock received $11.25 in cash and 0.1442 shares of Repligen common stock for each share held. The transaction expands Repligen's presence in the cell therapy market by adding BioLife’s biopreservation media portfolio, which supports commercially approved therapies and clinical trials. BioLife has ceased to exist as a separate legal entity and its stock will be delisted from Nasdaq. Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems for manufacturing biological drugs.
Repligen Corporation announced that Karen A. Dawes will retire from its Board of Directors effective September 30, 2026, following over twenty years of service. The filing states her departure is not due to any disagreement with the company regarding operations or policies. Repligen operates in the biotechnology industry, providing equipment and services for the development and manufacturing of biological drugs.
Repligen Corporation announced that the Hart-Scott-Rodino antitrust waiting period for its proposed acquisition of BioLife Solutions expired on September 3, 2026. The transaction involves Repligen acquiring all outstanding shares of BioLife common stock for $11.25 cash and 0.1442 shares of Repligen common stock per share. Completion remains subject to customary closing conditions, including adoption by BioLife's stockholders at a special meeting scheduled for October 5, 2026. Repligen Corporation operates in the biotechnology industry, providing equipment, consumables, and services for the development and manufacture of biological drugs.
Repligen Corporation reported second quarter 2026 financial results and updated its full-year guidance. Q2 revenue reached $204 million, a 12% year-over-year increase, while GAAP operating income remained flat at $14 million. Adjusted operating income rose 55% to $34 million, and adjusted diluted EPS was $0.54. The company raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09. Repligen also announced a definitive agreement to acquire BioLife Solutions to strengthen its cell therapy capabilities. The company operates in the life sciences industry, developing and commercializing bioprocessing technologies and systems for biological drug manufacturing.